Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 2/20 | 0.43 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 2/20 | 0.33 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.33 |
| ▸ | SNCA | P37840 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3465025 | 1.00 | PDE7A (0.43) | PDE7AKDM1ACYP2C19ADRA2AGAA | |
| SCHEMBL743696 | 0.84 | CYP2C19 (0.35) | PDE7AKDM1ACYP2C19ADRA2AGAA | |
| SCHEMBL3465090 | 0.78 | PDE7A (0.53) | PDE7AKDM1ACYP2C19ADRA2AGAA | |
| SCHEMBL28465895 | 0.72 | KDM1A (0.48) | PDE7AKDM1ACYP2C19ADRA2A | |
| SCHEMBL743822 | 0.66 | ADRA2A (0.43) | PDE7AKDM1ACYP2C19ADRA2ABACE1 | |
| SCHEMBL9176801 | 0.65 | AKR1B1 (0.60) | PDE7AKDM1ACYP2C19AKR1B1 | |
| SCHEMBL1972093 | 0.65 | TSHR (0.58) | PDE7AAKR1B1 | |
| SCHEMBL3465309 | 0.64 | KDM1A (0.43) | PDE7AKDM1ACYP2C19ADRA2A | |
| SCHEMBL3464559 | 0.64 | KDM1A (0.46) | PDE7AKDM1ACYP2C19ADRA2A | |
| SCHEMBL4640481 | 0.64 | KDM1A (0.61) | KDM1ACYP2C19ADRA2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168145-A1 | FUSED IMIDAZOLE DERIVATIVES AND USE THEREOF AS ALDOSTERONE SYNTHASE INHIBITORS | SPEEDEL EXPERIMENTA AG (CH) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168145-A1 | FUSED IMIDAZOLE DERIVATIVES AND USE THEREOF AS ALDOSTERONE SYNTHASE INHIBITORS | CYP21A2, CYP11B1, CYP17A1 | PDE7A 915/4885KDM1A 2819/4885CYP2C19 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.